David Ross Smith Sells 2,552 Shares of Charles River Laboratories International, Inc. (CRL) Stock

Charles River Laboratories International, Inc. (NYSE:CRL) insider David Ross Smith sold 2,552 shares of the company’s stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $67.10, for a total value of $171,239.20. Following the completion of the transaction, the insider now directly owns 11,671 shares in the company, valued at $783,124.10. The transaction was disclosed in a filing with the SEC, which is available at this link.

David Ross Smith also recently made the following trade(s):

  • On Thursday, June 8th, David Ross Smith sold 945 shares of Charles River Laboratories International stock. The shares were sold at an average price of $95.00, for a total value of $89,775.00.

Charles River Laboratories International, Inc. (CRL) opened at 99.71 on Friday. Charles River Laboratories International, Inc. has a 12-month low of $67.20 and a 12-month high of $102.32. The stock’s 50 day moving average price is $99.62 and its 200 day moving average price is $92.23. The company has a market capitalization of $4.75 billion, a PE ratio of 26.27 and a beta of 1.02.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, August 9th. The medical research company reported $1.29 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.22 by $0.07. Charles River Laboratories International had a net margin of 10.13% and a return on equity of 27.02%. The business had revenue of $469.13 million during the quarter, compared to the consensus estimate of $458.25 million. During the same period in the previous year, the firm posted $1.20 earnings per share. The business’s revenue for the quarter was up 8.1% compared to the same quarter last year. On average, equities analysts anticipate that Charles River Laboratories International, Inc. will post $5.10 EPS for the current fiscal year.

Charles River Laboratories International announced that its board has approved a stock buyback program on Wednesday, May 10th that authorizes the company to buyback $150.00 million in shares. This buyback authorization authorizes the medical research company to purchase shares of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s management believes its stock is undervalued.

WARNING: This story was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://sportsperspectives.com/2017/08/18/david-ross-smith-sells-2552-shares-of-charles-river-laboratories-international-inc-crl-stock.html.

Large investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in Charles River Laboratories International by 0.5% in the second quarter. Vanguard Group Inc. now owns 5,060,730 shares of the medical research company’s stock valued at $511,893,000 after buying an additional 27,217 shares during the last quarter. BlackRock Inc. increased its stake in Charles River Laboratories International by 4.6% in the second quarter. BlackRock Inc. now owns 4,022,882 shares of the medical research company’s stock valued at $406,913,000 after buying an additional 177,239 shares during the last quarter. FMR LLC increased its stake in Charles River Laboratories International by 23.8% in the second quarter. FMR LLC now owns 3,079,179 shares of the medical research company’s stock valued at $311,458,000 after buying an additional 591,066 shares during the last quarter. Ariel Investments LLC increased its stake in Charles River Laboratories International by 30.7% in the first quarter. Ariel Investments LLC now owns 2,060,420 shares of the medical research company’s stock valued at $185,335,000 after buying an additional 483,564 shares during the last quarter. Finally, State Street Corp increased its stake in Charles River Laboratories International by 2.3% in the second quarter. State Street Corp now owns 1,268,308 shares of the medical research company’s stock valued at $128,288,000 after buying an additional 28,365 shares during the last quarter. Institutional investors and hedge funds own 93.79% of the company’s stock.

Several research firms recently issued reports on CRL. Jefferies Group LLC reaffirmed a “buy” rating and issued a $121.00 price objective on shares of Charles River Laboratories International in a research report on Friday, June 30th. Zacks Investment Research cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Tuesday, July 25th. Citigroup Inc. reaffirmed a “neutral” rating and issued a $104.00 price objective (up from $91.00) on shares of Charles River Laboratories International in a research report on Wednesday, June 28th. Barclays PLC reaffirmed a “hold” rating and issued a $102.00 price objective on shares of Charles River Laboratories International in a research report on Wednesday, July 19th. Finally, BidaskClub cut Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. One analyst has rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $96.94.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Insider Buying and Selling by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply